ClinicalTrials.gg
CompletedNCT04763044Updated Jul 19, 2022Results posted

Evaluation of the Fluoride Dose Response Using In Situ Caries Model

A Phase 4 interventional study of 0 ppm F and 250 ppm F as MFP in Caries, sponsored by Procter and Gamble. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-19.

Sponsored by Procter and Gamble · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the fluoride dose response of different dentifrice fluoride concentrations - 0, 250, 1100 and 2800 ppm fluoride as sodium monofluorophosphate (MFP) and a fifth leg of 1100 ppm Stannous Fluoride (SnF2) using an in situ caries model.

02

Conditions studied

  • Caries
03

In context

Lead sponsor

Procter and Gamble is the lead sponsor of 83 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be between 18 and 85 years of age;
  • Provide written prior to participation and be given a signed copy of the informed consent form;
  • Be in general good health as determined by the Investigator based on a review of the health history/update for participation in the trial;
  • Be wearing a removable mandibular partial denture with sufficient room in one posterior buccal flange area to accommodate two 4 mm round enamel specimens and room on the same side to accommodate two 4 mm round specimens in the buccal surface of two posterior denture teeth;
  • Be willing and capable of wearing their removable partial denture 24 hours a day for four (4), three-week treatment periods;
  • Be willing to allow study personnel to drill specimen sites (as described in #iv) in their mandibular partial denture;
  • Be in good medical and dental health with no active caries or periodontal disease (NOTE: subjects presenting at screening with caries may continue in the study if their carious lesions are restored prior to beginning treatment 1);
  • Have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate ≥ 0.2 mL/min; gum base stimulated whole saliva flow rate ≥ 0.8 mL/min).

Exclusion criteria

Exclusion Criteria:

  • Currently being pregnant, intending to become pregnant during the study period, or breast feeding;
  • Currently having any medical condition that could be expected to interfere with the subject's safety during the study period;
  • Currently taking antibiotics or having taken antibiotics in the two weeks prior to beginning treatment 1;
  • Having participated in another clinical study or receipt of an drug within 30 days of beginning treatment 1; or
  • Taking fluoride supplements, required to use a fluoride mouth rinse, or have received a professional fluoride treatment in the two weeks preceding specimen placement;
  • Currently taking or have ever taken bisphosphonate drugs (e.g., Fosamax, Actonel and Boniva) for the treatment of osteoporosis.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
15 participants (actual)

Study arms

  • Other
    Period 1

    0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

    Drug: 0 ppm F · Drug: 250 ppm F as MFP · Drug: 1100 ppm as MFP · Drug: 2800 ppm F as MFP

  • Other
    Period 2

    0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

    Drug: 0 ppm F · Drug: 250 ppm F as MFP · Drug: 1100 ppm as MFP · Drug: 2800 ppm F as MFP

  • Other
    Period 3

    0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

    Drug: 0 ppm F · Drug: 250 ppm F as MFP · Drug: 1100 ppm as MFP · Drug: 2800 ppm F as MFP

  • Other
    Period 4

    0 ppm F (placebo, negative control), 250 ppm F as MFP (dose-response control), 1100 ppm F as MFP (reference), 2800 ppm F as MFP (dose-response control)

    Drug: 0 ppm F · Drug: 250 ppm F as MFP · Drug: 1100 ppm as MFP · Drug: 2800 ppm F as MFP

  • Other
    Period 5

    1100 ppm SnF2 toothpaste only

    Drug: 1100 ppm SnF2

Interventions

  • Drug0 ppm F

    Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

  • Drug250 ppm F as MFP

    Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

  • Drug1100 ppm as MFP

    Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

  • Drug2800 ppm F as MFP

    Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

  • Drug1100 ppm SnF2

    Each subject will be assigned to this treatment during the fifth period for this crossover study.

06

What researchers measure

Primary outcomes

  1. Enamel Fluoride Uptake (EFU)

    The EFU test will evaluate the level of fluoride in partially demineralized enamel specimens via the microdrill enamel biopsy technique by \[Sakkab et al., 1984\]. The calculated scores will be measured in μg F/cm2.

    Time frame: Evaluations will occur after 21 days of product use

Secondary outcomes

  1. Enamel Fluoride Uptake (EFU)

    The EFU test will evaluate the level of fluoride in partially demineralized enamel specimens via the microdrill enamel biopsy technique by \[Sakkab et al., 1984\]. The calculated scores will be measured in μg F/cm2.

    Time frame: Evaluations will occur after 7 days of product use

  2. Percent Surface Microhardness (SMH)

    The SMH test will evaluate changes in the mineral status of partially demineralized enamel specimens through use of a Wilson 2100 Hardness Tester. These scores will be calculated as a percent.

    Time frame: Evaluations will occur after 7 days of product use

  3. Enamel Fluoride Uptake (EFU)

    The EFU test will evaluate the level of fluoride in partially demineralized enamel specimens via the microdrill enamel biopsy technique by \[Sakkab et al., 1984\]. The calculated scores will be measured in μg F/cm2.

    Time frame: Evaluations will occur after 14 days of product use

  4. Percent Surface Microhardness (SMH)

    The SMH test will evaluate changes in the mineral status of partially demineralized enamel specimens through use of a Wilson 2100 Hardness Tester. These scores will be calculated as a percent.

    Time frame: Evaluations will occur after 14 days of product use

  5. Percent Surface Microhardness (SMH)

    The SMH test will evaluate changes in the mineral status of partially demineralized enamel specimens through use of a Wilson 2100 Hardness Tester. These scores will be calculated as a percent.

    Time frame: Evaluations will occur after 21 days of product use

07

Results

Posted Jul 19, 2022

Participant flow

Period 1
Participant flow — Period 1
Milestone0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF21100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF22800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2
Started3444
Completed3443
Not completed0001
Period 2
Participant flow — Period 2
Milestone0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF21100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF22800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2
Started3443
Completed3443
Not completed0000
Period 3
Participant flow — Period 3
Milestone0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF21100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF22800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2
Started3443
Completed3443
Not completed0000
Period 4
Participant flow — Period 4
Milestone0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF21100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF22800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2
Started3343
Completed3343
Not completed0000
Period 5
Participant flow — Period 5
Milestone0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF21100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF22800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2
Started3343
Completed2343
Not completed1000

Outcome measures

PrimaryEnamel Fluoride Uptake (EFU)

The EFU test will evaluate the level of fluoride in partially demineralized enamel specimens via the microdrill enamel biopsy technique by \[Sakkab et al., 1984\]. The calculated scores will be measured in μg F/cm2.

Time frame:
Evaluations will occur after 21 days of product use
Reported as:
Mean · μg F/cm^2
Enamel Fluoride Uptake (EFU)
μg F/cm^20 Ppm F (Placebo, Negative Control)250 Ppm F as MFP (Dose-response Control)1100 Ppm F as MFP (Reference)2800 Ppm F as MFP (Dose-response Control)1100 Ppm SnF2
Enamel Fluoride Uptake (EFU)2.28 ± 0.7094.51 ± 0.7098.78 ± 0.73614.05 ± 0.7097.43 ± 0.423
SecondaryEnamel Fluoride Uptake (EFU)

The EFU test will evaluate the level of fluoride in partially demineralized enamel specimens via the microdrill enamel biopsy technique by \[Sakkab et al., 1984\]. The calculated scores will be measured in μg F/cm2.

Time frame:
Evaluations will occur after 7 days of product use
Reported as:
Mean · μg F/cm^2
Enamel Fluoride Uptake (EFU)
μg F/cm^20 Ppm F (Placebo, Negative Control)250 Ppm F as MFP (Dose-response Control)1100 Ppm F as MFP (Reference)2800 Ppm F as MFP (Dose-response Control)1100 Ppm SnF2
Enamel Fluoride Uptake (EFU)3.13 ± 0.8815.20 ± 0.8828.20 ± 0.91613.52 ± 0.8509.11 ± 0.670
SecondaryPercent Surface Microhardness (SMH)

The SMH test will evaluate changes in the mineral status of partially demineralized enamel specimens through use of a Wilson 2100 Hardness Tester. These scores will be calculated as a percent.

Time frame:
Evaluations will occur after 7 days of product use
Reported as:
Mean · Percent SMH Recovery
Percent Surface Microhardness (SMH)
Percent SMH Recovery0 Ppm F (Placebo, Negative Control)250 Ppm F as MFP (Dose-response Control)1100 Ppm F as MFP (Reference)2800 Ppm F as MFP (Dose-response Control)1100 Ppm SnF2
Percent Surface Microhardness (SMH)15.92 ± 3.25922.50 ± 3.26422.42 ± 3.36035.61 ± 3.16026.32 ± 4.605
SecondaryEnamel Fluoride Uptake (EFU)

The EFU test will evaluate the level of fluoride in partially demineralized enamel specimens via the microdrill enamel biopsy technique by \[Sakkab et al., 1984\]. The calculated scores will be measured in μg F/cm2.

Time frame:
Evaluations will occur after 14 days of product use
Reported as:
Mean · μg F/cm^2
Enamel Fluoride Uptake (EFU)
μg F/cm^20 Ppm F (Placebo, Negative Control)250 Ppm F as MFP (Dose-response Control)1100 Ppm F as MFP (Reference)2800 Ppm F as MFP (Dose-response Control)1100 Ppm SnF2
Enamel Fluoride Uptake (EFU)3.86 ± 1.1417.23 ± 1.14111.53 ± 1.18518.92 ± 1.14112.65 ± 1.215
SecondaryPercent Surface Microhardness (SMH)

The SMH test will evaluate changes in the mineral status of partially demineralized enamel specimens through use of a Wilson 2100 Hardness Tester. These scores will be calculated as a percent.

Time frame:
Evaluations will occur after 14 days of product use
Reported as:
Mean · Percent SMH Recovery
Percent Surface Microhardness (SMH)
Percent SMH Recovery0 Ppm F (Placebo, Negative Control)250 Ppm F as MFP (Dose-response Control)1100 Ppm F as MFP (Reference)2800 Ppm F as MFP (Dose-response Control)1100 Ppm SnF2
Percent Surface Microhardness (SMH)10.49 ± 4.25818.62 ± 4.25824.76 ± 4.36938.08 ± 4.25828.28 ± 4.562
SecondaryPercent Surface Microhardness (SMH)

The SMH test will evaluate changes in the mineral status of partially demineralized enamel specimens through use of a Wilson 2100 Hardness Tester. These scores will be calculated as a percent.

Time frame:
Evaluations will occur after 21 days of product use
Reported as:
Mean · Percent SMH Recovery
Percent Surface Microhardness (SMH)
Percent SMH Recovery0 Ppm F (Placebo, Negative Control)250 Ppm F as MFP (Dose-response Control)1100 Ppm F as MFP (Reference)2800 Ppm F as MFP (Dose-response Control)1100 Ppm SnF2
Percent Surface Microhardness (SMH)4.76 ± 4.92111.14 ± 4.92117.51 ± 5.06833.38 ± 4.92117.91 ± 3.108

Adverse events

Collected over Each participant was monitored throughout the whole study, up to 4 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0 Ppm F (Placebo, Negative Control)0/14 (0%)0/14 (0%)3/14 (21.4%)
250 Ppm F as MFP (Dose-response Control)0/14 (0%)0/14 (0%)2/14 (14.3%)
1100 Ppm F as MFP (Reference)0/13 (0%)0/13 (0%)2/13 (15.4%)
2800 Ppm F as MFP (Dose-response Control)0/14 (0%)0/14 (0%)5/14 (35.7%)
1100 Ppm SnF20/13 (0%)0/13 (0%)0/13 (0%)
Most frequent other events
Showing 10 of 11
Most frequent other events
Event0 Ppm F (Placebo, Negative Control)250 Ppm F as MFP (Dose-response Control)1100 Ppm F as MFP (Reference)2800 Ppm F as MFP (Dose-response Control)1100 Ppm SnF2
Tooth BrokenGastrointestinal disorders0/140/141/130/140/13
Neck PainInjury, poisoning and procedural complications0/140/141/130/140/13
CoughingRespiratory, thoracic and mediastinal disorders1/140/140/130/140/13
Irritation MouthGastrointestinal disorders1/141/140/130/140/13
Edentulous Ridge ErythmeaGastrointestinal disorders1/140/140/130/140/13
VaginitisReproductive system and breast disorders0/141/140/130/140/13
Renal Kidney TumorRenal and urinary disorders0/140/140/131/140/13
Irritation GumGastrointestinal disorders0/140/140/131/140/13
Irritation TongueGastrointestinal disorders0/140/140/131/140/13
Lung CancerRespiratory, thoracic and mediastinal disorders0/140/140/131/140/13

Baseline characteristics

Age, Continuous
Age, Continuous(years)0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF21100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF22800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2Total
Mean69.7 ± 8.3372.5 ± 4.5169.7 ± 9.5076.3 ± 9.3272.2 ± 7.75
Sex: Female, Male
Sex: Female, Male(Participants)0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF21100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF22800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2Total
Female12429
Male22026
Race (NIH/OMB)
Race (NIH/OMB)(Participants)0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF21100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF22800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American02349
White22105
More than one race00000
Unknown or Not Reported10001
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF21100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF22800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2Total
Count of participants————0
Region of Enrollment
Region of Enrollment(participants)0 Ppm MFP, 250 Ppm MFP, 1100 Ppm MFP, 2800 Ppm MFP, 1100 Ppm SnF2250 Ppm MFP, 2800 Ppm MFP, 0 Ppm MFP, 1100 Ppm MFP, 1100 Ppm SnF21100 Ppm MFP, 0 Ppm MFP, 2800 Ppm MFP, 250 Ppm MFP, 1100 Ppm SnF22800 Ppm MFP, 1100 Ppm MFP, 250 Ppm MFP, 0 Ppm MFP, 1100 Ppm SnF2Total
United States344415
08

Study locations

1 site
  • Oral Health Research Institute
    Indianapolis, Indiana 46202, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Jul 2021, 4 months.

Results were first posted in Jul 2022, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2021
First posted
Feb 21, 2021
StartActual
Mar 1, 2021
Primary completionActual
Jul 21, 2021
CompletionActual
Jul 21, 2021
Results first posted
Jul 19, 2022
Last update
Jul 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04763044
Lead sponsor
Procter and Gamble
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
Mar 1, 2021
Primary completion
Jul 21, 2021
Completion
Jul 21, 2021
Results posted
Jul 19, 2022
Last update
Jul 19, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion